Ethical challenges in preclinical Alzheimer's disease observational studies and trials:Results of the Barcelona summit by Molinuevo, José L et al.
  
 
 
 
Edinburgh Research Explorer 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Ethical challenges in preclinical Alzheimer's disease
observational studies and trials
Citation for published version:
Molinuevo, JL, Cami, J, Carné, X, Carrillo, MC, Georges, J, Isaac, MB, Khachaturian, Z, Kim, SYH, Morris,
JC, Pasquier, F, Ritchie, C, Sperling, R & Karlawish, J 2016, 'Ethical challenges in preclinical Alzheimer's
disease observational studies and trials: Results of the Barcelona summit', Alzheimer's & Dementia.
https://doi.org/10.1016/j.jalz.2016.01.009
Digital Object Identifier (DOI):
10.1016/j.jalz.2016.01.009
Link:
Link to publication record in Edinburgh Research Explorer
Document Version:
Publisher's PDF, also known as Version of record
Published In:
Alzheimer's & Dementia
Publisher Rights Statement:
Under a Creative Commons license
General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s)
and / or other copyright owners and it is a condition of accessing these publications that users recognise and
abide by the legal requirements associated with these rights.
Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer
content complies with UK legislation. If you believe that the public display of this file breaches copyright please
contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and
investigate your claim.
Download date: 11. May. 2020
Q12
Q2
Q4
Alzheimer’s & Dementia- (2016) 1-9
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
5455
56
57
58
59
60
61Perspectives
Ethical challenges in preclinical Alzheimer’s disease observational
studies and trials: Results of the Barcelona summit62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79Jose L. Molinuevoa,*, Jordi Camib, Xavier Carnec, Maria C. Carrillod, Jean Georgese,
Maria B. Isaacf, Zaven Khachaturiang, Scott Y. H. Kimh, John C. Morrisi, Florence Pasquierj,
Craig Ritchiek, Reisa Sperlingl, Jason Karlawishm
aBarcelonabeta Brain Research Center, Pasqual Maragall Foundation, Barcelona, Spain
bPompeu Fabra University and Pasqual Maragall Foundation, Barcelona, Spain
cClinical Pharmacology Department, Hospital Clinic and IDIBAPS, Barcelona, Spain
dMedical & Scientific Relations, Alzheimer’s Association, Chicago, IL, USA
eAlzheimer Europe, Luxembourg, Luxembourg
fEuropean Medicines Agency (EMA)
gThe Campaign to Prevent Alzheimer by 2020 (PAD2020), Potomac, MD, USA
hDepartment of Bioethics, Clinical Center, National Institutes of Health, Bethesda, MD, USA
iWashington University School of Medicine, St Louis, MO, USA
jInserm 1171, Universite Lille2, CHU, Memory Centre Lille, France
kCentre for Clinical Brain Sciences, University of Edinburgh, UK
lCenter for Alzheimer Research and Treatment, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA
mDepartment of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA80
81
82Abstract Alzheimer’s disease (AD) is among themost significant health care burdens. Disappointing resultsThe authors’ perso
made on behalf of or
the DHHS, the US Go
their committees or w
J.L.M. has provide
monitoring board mem
Eisai, Janssen-Cilag,
Health Care, Merz, M
Boehringer-Inghelmei
Neither J.M. nor his fa
funds or other extern
biotechnology compa
http://dx.doi.org/10.10
1552-5260/ 2016 Th
83
84
85
86
87
88
89
90
91
92
93
94from clinical trials in late-stage AD persons combined with hopeful results from trials in persons with
early-stage suggest that research in the preclinical stage of AD is necessary to define an optimal
therapeutic success window. We review the justification for conducting trials in the preclinical stage
and highlight novel ethical challenges that arise and are related to determining appropriate
risk-benefit ratios and disclosing individuals’ biomarker status. We propose that to conduct clinical
trials with these participants, we need to improve public understanding of AD using unified
vocabulary, resolve the acceptable risk-benefit ratio in asymptomatic participants, and disclose or
not biomarker status with attention to study type (observational studies vs clinical trials). Overcoming
these challenges will justify clinical trials in preclinical AD at the societal level and aid to the
development of societal and legal support for trial participants.
 2016 The Alzheimer’s Association. Published by Elsevier Inc. All rights reserved.95
96Keywords: Alzheimer’s disease; Preclinical AD; Ethics; Asymptomatic97nal views should not be understood or quoted as being
reflecting the official position or policies of the NIH,
vernment, the European Medicines Agency, or any of
orking parties.
d scientific advice or has been an investigator or data
ber receiving consultancy fees from Novartis, Pfizer,
Lundbeck, Roche, Bayer, Bristol-Myers Squibb, GE
SD, GlaxoSmithKline, Astra-Zeneca, Avid, Lilly,
n, Biokit, Piramal, IBL, and Fujireibio-Europe.
mily own stock or have equity interest (outsidemutual
ally directed accounts) in any pharmaceutical or
ny. J.M. has participated or is currently participating
in clinical trials of antidementia drugs sponsored by the following com-
panies: Janssen Immunotherapy, Pfizer, Eli Lilly/Avid Radiopharmaceuti-
cals, SNIFF (The Study of Nasal Insulin to Fight Forgetfullness) study,
and A4 (the antiamyloid treatment in asymptomatic Alzheimer’s disease)
trial. J.M. has served as a consultant for Lilly USA, ISIS Pharmaceuticals,
and Charles Dana Foundation. He receives research support from Eli
Lilly/Avid Radiopharmaceuticals and is funded by NIH grants
#P50AG005681; P01AG003991; P01AG026276; and U19AG032438.
*Corresponding Q3author. Tel.: 134 93 316 0990; Fax:---.
E-mail address: jlmolinuevo@fpmaragall.org
16/j.jalz.2016.01.009
e Alzheimer’s Association. Published by Elsevier Inc. All rights reserved.
SSU 5.4.0 DTD  JALZ2137_proof  14 March 2016  8:42 pm  ce
98
99
100
101
102
103
104
105
106
107
108
109
Q5
J.L. Molinuevo et al. / Alzheimer’s & Dementia- (2016) 1-92
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
2311. Introduction
By the year 2030, 76 million people worldwide will
suffer from dementia, with most cases being caused by
Alzheimer’s disease (AD) [1]. Despite the considerable
advances in our understanding of the neuropathologic
processes that underpin AD, academic and industry research
programs that develop mechanism-based therapies,
including those directed against b-amyloid have yet to
produce meaningful clinical benefits [2]. Consequently,
one of the biggest questions that the AD research community
faces is whether clinical trials have so far included
participants who have already surpassed the optimal
therapeutic window for intervention, together with the
need to ensure the presence of AD pathology through
biomarkers.
In 1984, the National Institute of Neurological and
Communicative Disorders and Stroke-Alzheimer’s Disease
and Related Disorders Association (NINDS-ADRDA, now
the Alzheimer’s Association) published for the first time
the clinical diagnostic criteria for AD [3]. Almost 30 years
later, the progress in our scientific understanding of
the neuropathology that precedes clinical symptoms
prompted the scientific community to redefine AD as a
pathologic continuum. Both the International Working
Group and the US National Institute of Aging with the
Alzheimer’s Association (NIA-AA) released revised
guidelines that incorporated biomarkers to identify
individuals at risk of developing AD dementia [4–8]. Both
criteria subdivide AD development into three stages:
preclinical (abnormal biomarkers and no or only subtle
cognitive impairment), mild cognitive impairment (MCI)
due to AD or prodromal AD (defined as the presence of
abnormal pathophysiological biomarkers and episodic
memory impairment) and dementia (abnormal biomarkers
and clear cognitive and functional impairment).
One significant advance in our understanding of AD is
that it has two components: a neuropathologic one, which
remains asymptomatic during years, and a clinical one,
which starts with a MCI stage followed by a dementia one.
Convergent biomarker and imaging findings from autosomal
dominant AD mutation carriers, genetic at-risk and age
at-risk cohorts suggest that the pathophysiological process
of AD starts over a decade before the dementia stage
[9–14]. This asymptomatic phase, referred to as preclinical
AD, has given us an unprecedented opportunity to perform
observational studies and trials to intervene at earlier
stages of the continuum and delay the onset of clinical
decline and ultimately dementia. In this scenario, trials in
mild moderate AD have been consistently negative during
the last decade [15], and although we are still waiting for
the results of ongoing prodromal AD trials, intervention
studies on asymptomatic individuals appear as highly
relevant and promising, before substantial irreversible
neuronal network dysfunction and loss, associated with
overt clinical symptoms, have occurred.SSU 5.4.0 DTD  JALZ2137_proof Conducting preclinical AD clinical trials gives rise to a
variety of novel ethical and policy challenges. These include
whether to disclose genetic and/or biomarker results to an
individual, the need to determine an acceptable risk-benefit
ratio in asymptomatic participants and the legal protection
of participants from insurance policies. The ethical
framework that guides clinical research can be seen as a
balancing among the interests of the participants and society
on one side, as well as the research challenges on the other
[16]. To review and discuss the novel ethical challenges
that need to be overcome for successful performance of trials
in the preclinical stage of AD, a multistakeholder group met
in a 1-day summit entitled “Ethical challenges of future
Alzheimer’s disease clinical research” held in Barcelona in
October 2014. This reunion was organized by the Barcelona-
beta Brain Research Center, the research institute where the
Pasqual Maragall Foundation conducts all its scientific
activities devoted to clinical research for the prevention of
AD. This discussion group included experts from academia,
including AD researchers and bioethicists, patients’
organizations and regulatory agencies. This article summa-
rizes the outcome of that meeting, where these ethical and
policy challenges were debated and recommendations to
address them throughout the research process were
proposed, discussed, and agreed.2. The scientific basis of the preclinical stage and
prevention strategies
The prevailing hypothesis for AD pathogenesis, the
amyloid cascade hypothesis, assumes several causal events
that begin with the accumulation of b-amyloid in the brain
followed by tau hyperphosphorylation and then neuronal
degeneration. In addition to advanced age, the risk of
developing AD is increased among persons with certain
genetic variants. Autosomal dominant AD (ADAD),
characterized by pathogenic mutations in one of three
genes—the b-amyloid precursor protein (APP), Presenilin
1 (PSEN1), and Presenilin 2 (PSEN2)—provide almost
certain risk (w100%) of developing symptomatic AD
[17]. In addition, APOLIPOPROTEIN E ε4 (APOE-ε4)
allele carriers have a significantly higher risk of developing
symptomatic AD when compared to noncarriers [18].
Specifically, the risk of AD has been shown to be 2.6 times
higher for people with the APOE-ε2/4 genotype relative to
APOE-ε3/3 individuals and 3.2 and 14.9 times higher for
APOE-ε3/4 and APOE-ε4/4 persons, respectively [19].
Our understanding of preclinical AD indicates that
biomarker abnormality occurs in a temporal manner where
it has been demonstrated that abnormally low cerebrospinal
fluid (CSF) b-amyloid 42 (Ab42) and cerebral amyloid
deposits precede elevated CSF tau, topographical cerebral
injury, and cognitive decline [20]. New data from recently
initiated studies such as EPAD (European Prevention of
Alzheimer’s Dementia), PREVENT Research Programme14 March 2016  8:42 pm  ce
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will further support these disease models. The timeframe for
these pathologic changes may be as long as 25 years before
symptom onset. In presymptomatic ADAD individuals, CSF
Ab42 decline has been observed 25 years before clinical
symptoms, whereas b-amyloid deposition (measured by
amyloid imaging) and elevated CSF tau have been detected
15 years before symptom onset [9]. The preclinical stage
of AD can be further subdivided into three stages:
stage 1—asymptomatic amyloidosis (positive amyloid
imaging, low CSF Ab42); stage 2—amyloidosis and
neurodegeneration (neuronal dysfunction; high CSF tau);
and stage 3—amyloidosis, neurodegeneration, and subtle
or subjective cognitive decline (this decline has yet to be
operationalized but presumably falls short of prodromal
AD or MCI due to AD) [8]. The validity of these
stages has been suggested by a retrospective study of
asymptomatic individuals which demonstrated that the
5-year progression rate was 2% for participants classified
as normal, 11% for those in stage 1, 26% for stage 2, and
56% for stage 3 [14].
Retrospective and prospective studies are useful to
indicate the likely causal pathways that lead from a healthy
aging brain to a diseased brain, but they cannot definitively
establish the validity of these pathways. The best method
to establish this validity is to intervene using a randomized
and controlled experiment with an antiamyloid drug in
asymptomatic persons who exhibit amyloid-positive PET
scans, before substantial loss of synaptic and neuronal
integrity. In that sense, the only way to validate the causality
of a pathway is through a clinical trial in which the active
drug is able to prevent the deleterious effect of the proposed
pathogenic process. Hence, a positive prevention trial not
only validates the efficacy of the drug but also the causality
of the treated pathway. This model has been used in other
diseases where treatment in asymptomatic individuals has
resulted in significant benefit for patients and society. For
instance, in the United States, 28% of the population aged
40 years and over uses cholesterol-lowering medication on
a regular basis. The appropriate widespread use of these
medications has with no doubt prolonged the lives of
millions [21]. The origin of these drugs was a pioneer
study in asymptomatic familial hypercholesterolemia
patients [22].
In our field, to arrest or at least delay, the onset of cogni-
tive decline in subjects showing amyloid accumulation is
termed secondary prevention. On the other hand, primary
prevention strategies directed toward preventing the initial
cortical amyloid deposition would significantly impact the
prevalence of AD. Secondary prevention clinical trials in
persons with preclinical AD that are biomarker positive
and asymptomatic are already occurring and summarized
here in Table 1 [23–26]. Collectively, these studies will
help ascertain if secondary prevention is a valid approach
for AD, and whether clinical trials of 3 to 5 years are
sufficient for delaying cognitive decline [27]. RecentSSU 5.4.0 DTD  JALZ2137_proof worldwide initiatives are also aiming to maximize efficiency
to obtain a clinical signal and develop sensitive outcomes for
detecting early decline, through new trial designs. The first
of these initiatives, funded by the Innovative Medicines
Initiative under the topic “European platform for proof of
concept for prevention in Alzheimer’s disease” is the
EPAD project. This project aims at delivering an adaptive
trial for secondary prevention of AD. Sister initiatives in
the upcoming years will be launched in the United States
and Canada.
The motivation for secondary prevention trials in AD
dementia is based on the observation that delaying the onset
of AD dementia by as little as 5 years would decrease the
total number of Americans aged 65 years and older with
AD from 5.6 million in 2010 to 4 million by 2020 [28].
Longitudinal studies have shown that as many as
30%–40% of elderly healthy individuals exhibit signs of
b-amyloid accumulation [29]. In addition, many individuals
with b-amyloid and tau accumulation exhibited subtle
cognitive decline antemortem [30]. Furthermore, several
studies have also shown that cognitively normal individuals
with abnormal levels of AD biomarkers exhibit longitudinal
cognitive decline [31,32]. These individuals are at an
increased risk for progressing to cognitive impairment
[33,34].3. The ethical challenges
When considering preclinical AD trials, two ethical
issues of special importance arise. First, because asymptom-
atic persons are exposed to novel agents for an extended
period, the design of the trial must ensure that the potential
benefits justify the burden and risk for the participants.
Second, many prevention trials will enrich their study
population through genetic and other biological risk factors
that will be screened by genetic and/or imaging techniques.
As these tests are normally discouraged in routine clinical
practice and therefore, a person would not normally receive
this information unless participating in prevention trials, the
issue of disclosure of such information must be carefully
addressed [35–37].3.1. Risk-benefit considerations
One of the issues we face when considering the clinical
therapeutic window for preclinical studies is that the earlier
we are in the disease process, the longer clinical trials aimed
to detect change will have to last. On a practical level, this
will result in screening an increased number of participants
to find the right population and longer follow-up times to
detect change. For example, the A4 study estimates that to
enroll over 1000 individuals, over 5000 people must be
screened, over 3000 will have to undergo PET amyloid
imaging, and that it will take 3 years to detect any effect
of the treatment [25]. If future longitudinal studies in
preclinical individuals involve widening the biomarker14 March 2016  8:42 pm  ce
Table 1
Secondary Q1prevention clinical trials in Alzheimer’s disease
DIAN-TU API-ADAD A4 TOMMORROW API-APOε4
Target population Autosomal dominant AD Autosomal dominant AD Cognitively normal,
beta-amyloid
positive
Cognitively normal with
genetic risk
Cognitively normal
with genetic risk
Specific
characteristics
ADAD mutation carriers PSEN1 E280 A mutation
carriers
Positive brain
amyloid PET
TOMM40/APOE genotype Homozygous
APOε4 genotype
Estimated
enrollment
210 300 1150 5800 1340
Phase Phase II/III Phase II Phase III Phase III Phase II/III
Compound Gantenerumab,
Solanezumab
Crenezumab Solanezumab Pioglitazone CAD106, CNP520
Mechanism Anti-Ab antibodies Anti-Ab antibody Anti-Ab antibody PPAR-g agonist Ab vaccine & BACE
inhibitor
Status Recruiting Recruiting Recruiting Recruiting Not yet recruiting
Primary outcome Composite cognitive
test score
Composite cognitive test
score
Composite cognitive
test score
Time to diagnosis of MCI
due to AD
Time to diagnosis of
MCI due to AD,
composite cognitive
test score
Study duration 4 years 5 years 3 years 5 years 5 years
Study identifier NCT01760005 NCT01998841 NCT02008357 NCT01931566 NCT02565511
Reference Moulder et al., 2013 [23] Reiman et al., 2011 [24] Sperling et al., 2014 [25] Roses et al., 2014 [26] Reiman et al., 2011 [24]
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475status to incorporate individuals with lower biomarker
levels, the number of participants needed and the length of
follow-up are likely to increase.
Overall, future longitudinal studies that prolong partici-
pants’ exposure to interventions will place a significantly
greater procedural burden on individuals; the longer these
studies last, the greater the procedural burden will be. Based
on the current biomarker technologies and the regulatory
landscape-enrolling participants with even lower levels of
b-amyloid accumulation (compared to current studies) will
require an evaluation of what level of risk is ethical to offer
as a potential exposure.
One important factor in determining the acceptable
risk-benefit ratio is to better understand the public’s values
regarding this issue. However, this will require improving
public understanding of the relevant issues, such as the
probabilistic over deterministic nature of biomarkers. This
may be accomplishable through public messaging and other
educational methods. Indeed, the history of developing
treatments for serious and life threatening disease such as
AIDS and multiple sclerosis (MS) shows how decisions
about what risks are acceptable in the pursuit of a treatment
are part of a negotiated social order that engages expert
clinicians, regulators, and patients. In the case of AIDS,
the patient community moved trialists and regulators to
adopt trial designs that might expose subjects to more active
intervention-derived risk but at the same time expedited the
discovery of whether an intervention was effective [38].
Input from patient advocates was also influential in the
FDA’s decision to permit natalizumab as a treatment for
MS despite the risk of progressive multifocal leukoence-
phalopathy ([39]; note “There is an active ongoing
discussion among regulators, researchers, and patient advo-
cates seeking successful ways to continue development ofSSU 5.4.0 DTD  JALZ2137_proof promising drugs while limiting the hazard to patients who
take these medications.”) In a similar manner, input from
the patient community can help the AD research community
understand what degree of risk is acceptable when drugs
may, for example, present risks to brain function from side
effects such as amyloid-related imaging abnormalities.
A basic ethical principle in clinical research is “respect
for persons”, recognizing that some individuals are not
autonomous, which sometimes can be the case among
Alzheimer’s patients. The requirement for informed consent
is designed to uphold this ethical principle and is based on
clear language and unbiased information on the issue at
stake. One benefit of conducting trials in preclinical AD
(over studies with symptomatic individuals) is that asymp-
tomatic persons are in a much better position to protect their
own welfare and to express their values regarding what risk
is acceptable for them in providing informed consent. We
know that people volunteer for clinical trials for a variety
of reasons and indeed, the distinct types of benefit
outcomes from research (namely direct, collateral, and
aspirational) must be specifically specified when obtaining
the participants informed consent [40]. One perceived
benefit of interventional trials is the possibility of
receiving an efficacious therapeutic agent or combination
of agents/interventions (direct benefit). Hence, individuals
enroll in research because they consider it may be of benefit
to their own health, and this benefit outweighs the risks of the
research. Furthermore, there may be associated indirect
potential benefits for clinical trial participation (collateral
benefit). For example, participation may yield positive
psychological impact on self-confidence, self-worth, and
the perceived benefit that the volunteer provides societal
value [41] and even free physical examination and testing.
In addition, it has also been shown that altruism (aspirational14 March 2016  8:42 pm  ce
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entering a clinical trial [42].540
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5973.2. Disclosure of risk marker status
Another fundamental consideration that is integral in the
ethical assessment of clinical research is the potential harm
and benefit of disclosure [35–37]. Although genetic testing
and biomarker status differ in several ways such as
imminence of risk, stability of the results, and direct
implications for consanguineous family members [37],
disclosure of any genetic or biomarker status is a complex
task that requires specific training and ability to convey
uncertainty. Therefore, discussing the risks and benefits of
disclosure can largely be regarded as indistinguishable
between genetic and biomarker disclosure. It has already
been shown that knowledge imbalances between scientific
and medical concepts related to genetics as well as medical
practices can occur, even in study populations with a
relatively high educational status and genetic knowledge
[43]. When considering disclosure, the physician or
researcher has the responsibility of educating the patient
on the risks and benefits of learning their genetic/biomarker
status. In the Risk Evaluation and Education of AD
(REVEAL) study, pictures, graphic illustrations, and
animations are used to explain the risk of developing AD,
especially in the case when there is a genetic predisposition
[44,45].
The decision to learn one’s genetic or biomarker status is
that of the study participant, especially in trials in which
participants are cognitively normal. From an ethical
standpoint, the concern with disclosing a person’s biomarker
status is that this could induce psychological stress. Previous
studies that have examined the impact of genetic disclosure
have found that there are no overall significant differences in
the levels of anxiety experienced by individuals who learn
their APOE status compared to individuals who do not learn
this information [46]. Nevertheless, those who were
informed that they were APOEε4 noncarriers had a
significantly lower level of test-related distress. In this
case, the study was performed over the course of 1 year;
however, when considering preclinical studies that may
last for many years during which participants are implicitly
reminded of their genetic or biomarker status, the burden of
knowing one’s status must be thoroughly studied for AD. In
that sense, the preclinical and early diagnoses of
Huntington’s disease (HD) are associated with an increased
risk of suicidal behavior. On the other hand, this figure
coincides with the suicide rates previously reported for
symptomatic individuals diagnosed with HD [47].
Therefore, more studies are necessary to prevent this harm
from being neglected.
Another consideration in whether to disclose gene or
biomarker results is the concept of a stereotype threat
whereby providing a label to the individual elicits behaviorSSU 5.4.0 DTD  JALZ2137_proof and/or characteristics that are perceived as belonging to
this label. This is illustrated in a recent study where APOEε4
carriers whowere told had poorer performances on cognitive
tests compared to their nondisclosure counterparts who
carried the same alleles [48].
Given the potential adverse effects of knowing one’s risk,
should the AD research community always conduct trials
that do not disclose gene or biomarker results? In answering
this question, it is important to examine the public’s
perception of predictive testing (with the assumption of
receiving the results). An Alzheimer Europe survey of
random samples from five different countries found that
approximately two-thirds of respondents would get a
medical test which would tell them whether they would
get AD before they had symptoms [49]. In addition, other
studies have shown that disclosure of an “at-risk” status
can also positively impact peoples’ lives. Studies that
followed-up disclosure groups found that APOEε4
carriers more frequently took measures to reduce risk,
compared to APOEε4 non-carriers, implementing health-
related behavioral changes [50,51].
Research designs that disclose risk information can
further protect subjects by implementing safeguards. Before
disclosing genetic or biomarker status, the investigator
ought to assess if the potential participant is emotionally
capable of enrolling in a study. Data from the REVEAL
study clearly show that those who exhibited a high degree
of emotional stress before undergoing genetic testing were
more likely to have emotional difficulties after disclosure
[46], although this does not preclude those subjects for
participating in a study. Furthermore, for those who are
included, one way to reduce potential stress is to provide
continuous counseling throughout the study or through
social forums where open discussions can take place as
this has been shown to have a direct positive effect on stress
and anxiety [52].
Briefly, the main risks deriving from disclosure include
placing a cloud of uncertainty over participants that may
affect their daily lives and/or performance in specific
procedures and the complexity of conveying uncertainty.
On the other hand, main benefits comprise the protection
of biomarker-negative individuals from risks and harms
related to clinical studies’ procedures, and the positive
impact that this information may have on people’s lives.
According to these appreciations, we recommend to disclose
or not biomarker status with attention to study type
(observational studies vs clinical trials; see below).
When considering the prospect of long-term preclinical
studies, we recommend that for observational studies, unless
the aim of the study was to investigate the impact of
disclosure on outcome, the most scientifically valid method
is a blinded enrollment study in which genetic or biomarker
status is not disclosed. This will avoid the impact of knowing
on participants’ welfare and cognitive performance, together
with disclosing clinically nonrelevant biomarker or genetic
status of uncertain prognosis.14 March 2016  8:42 pm  ce
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719For interventional studies, protecting the subjects that
are biomarker negative from risks and harms related to
the trial’s procedures prevail over the motivations noted
above to support blinded enrollment. Furthermore, a recent
systematic analysis comparing the ethics of transparent
(i.e., requiring disclosure) enrollment versus blinded
enrollment in AD prevention studies provided strong
arguments that there are no special risk benefit, informed
consent, or fair participant selection issues that require
blinded enrollment. Therefore, if it is feasible to conduct
a scientifically valid trial with a transparent enrollment
study design, we recommend this design for interventional
studies. Exceptionally, the feasibility of a transparent
design will depend on the characteristics of the study pop-
ulation. In the DIAN-TU study, the potential participant
pool is quite small consisting of relatively young persons
at risk for familial AD. For such persons, whether to learn
that they will almost certainly develop AD at a relatively
young age is a very momentous and complex question. It
has been the case that even when offered the opportunity
to have genetic counseling and commercial genetic testing
to learn their mutation status at no cost to themselves, the
majority decline as they do not wish to know, as has been
the case in similar populations in previous studies [53–55].
Thus, it would not be feasible to conduct a scientifically
valid study involving DIAN-TU registry participants using
a transparent enrollment (i.e., requiring disclosure of
genetic status).
By contrast, the A4 trial draws from a large pool of poten-
tial participants who have an elevated probabilistic increase
in risk for AD and requires that the participants are willing to
learn their amyloid biomarker status. Most of the partici-
pants are in a much later stage of life and may in fact have
a greater motivation to learn about factors that may increase
their risk of AD. Thus, the feasibility of a transparent enroll-
ment design is much greater. This has been confirmed in our
experience so far in the A4 trial [56,57].
An important additional argument for the transparent
design (i.e., requiring gene or biomarker disclosure) is that
this design better reflects the future clinical practice of
drug prescription to those who learn that they have an altered
AD biomarker. A design that includes biomarker disclosure
would therefore more closely resemble routine clinical prac-
tice and so can provide information about the success of this
potential clinical future. Furthermore, blinded designs
require risk-negative participants to be enrolled to avoid
“disclosure by enrollment”; thus, transparent enrollment
has the advantage of minimizing the number of participants
enrolled to attain sufficient statistical power to obtain clini-
cally meaningful results. New trials currently under design,
like the new API trial with APOEε4 homozygotes, will be
disclosing APOE status, through a standardized genetic
counseling protocol [46].
Finally, we know that AD manifests its pathology years
before it manifests its clinical symptoms and hence, from a
biological perspective, the disease is already present andSSU 5.4.0 DTD  JALZ2137_proof the term preclinical AD is accurate. Nevertheless, we have
to be especially careful in how we address and communicate
the preclinical stage of the disease to study participants. Tak-
ing into account that not all participants in preclinical studies
will develop the clinical symptoms of the disease, one useful
term to address them could be asymptomatic at risk for
cognitive impairment.4. Social, legal, and policy challenges
The foremost ethical obstacle that we, as a society, need
to overcome involves the concept of social justice—namely,
justice in terms of the distribution of wealth, opportunities,
and privileges within a society. Can one therefore justify sec-
ondary prevention as a priority for the public administration
when there is insufficient support and treatment for indivi-
duals that suffer from dementia? Indeed, we envisage that
conducting trials in preclinical AD will increase the overall
awareness of AD that should, in turn, improve support and
treatment for current AD sufferers. Nevertheless, currently,
between half and three quarters of people with dementia
have no formal diagnosis [58–60]. Furthermore, for those
that are diagnosed with AD many do not receive their
diagnosis, and for those that do it there can be a
substantial delay between diagnostic tests and receiving
the diagnosis [61,62]. In a recent special report of the
Alzheimer’s Association Facts & Figures, only 45% of
individuals diagnosed with Alzheimer’s disease were
notified of their diagnosis.
The first step to achieve this is the need to develop a
uniform language (currently under development by
expert committees through both the Alzheimer’s
Association and Alzheimer’s Europe) to reinforce a single
message to the public and policy makers. By unifying the
message from clinical research, we can increase the
awareness of AD clinical trials taking place. Increasing
awareness will improve public understanding toward
the severity of the disease as it has been shown that
individuals with close personal ties to patients with AD are
more likely (than those without) to view AD as a major
concern [63]. Consequently, this will not only reduce the
number of undiagnosed individuals but will also serve to
improve willingness to pursue predictive genetic and
biomarker testing that may facilitate future asymptomatic
enrollment.
Changing the public perception of AD and predictive
testing also requires the introduction of legal changes to
protect prospective participants. Currently, there is limited
protection for individuals who wish to participate in
preventative clinical trials. For example, in the United
States, the Genetic Information Nondiscrimination Act
(GINA) prohibits discrimination by health insurers or
employers based on genetic information. GINA protects
individuals with known genetic markers who have not
demonstrated “disease manifestation” of a condition that is
consistent with the genetic marker [64]. By contrast,14 March 2016  8:42 pm  ce
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841European protection of an individual’s genetic information
differs among governments [65]. The legal mechanisms
for reacting against breaches of the right to privacy in
Europe are based on Directive 95/46/CE. However, this
Directive has been differently transposed in different
member states. Although in some countries (such as
Belgium, Spain, and the Netherlands), privacy is
recognized as a constitutional right, others such as Germany,
Italy, Denmark, and France do not have this specific
recognition.
At present, there are no legal safeguards that protect an
individual’s biomarker data and without adequate
protection, the prospect of participating in a secondary
prevention trial may significantly impact an individual’s
ability to have access to an adequate health insurance,
insurance coverage, and working potential. To implement
change, governmental bodies will need to first recognize
biomarkers through policy bodies such as the FDA (Food
and Drug Administration) and EMA (European Medicines
Agency). At the time of writing, both the FDA and the
EMA are preparing guidelines on the use of biomarkers in
AD preclinical research. The outcome of these efforts will
play an important role in future health and legal policy for
AD research. In addition, current prevention studies,
together with future ones, will provide information of the
meaning of a positive beta-amyloid PET scan that may
change with the gain of further knowledge, and education
about the risks and benefits of beta-amyloid PET imaging,
assess the participant’s readiness and willingness to receive
the result and, where positive results are disclosed, monitor
the individual’s well being. An investigator taking part in
such research has the responsibility to make sure that the
study is taking steps to minimize disclosure of the result in
the medical record, and the participant should feel free to
ask whether this is the case.
One final challenge that faces the future of trials in
preclinical AD is the financial cost of such research
initiatives. The patent life gives the manufacturer a
maximum of 20 years of exclusive ownership since initial
filing. If preclinical AD trials are to last around 5 years,
the likelihood that pharmaceutical companies can fund
them and achieve profit from successful therapeutic agents
is improbable. Therefore, it is very likely that public
financial support will be required to complement private
funding to support future AD clinical trials. Developments
to tackle this challenge are already a reality in the United
States and Europe. In the United States, both DIAN-TU
[23] and API are the result of a public-private partnership;
whereas in Europe, the EPAD project aims to deliver a
standing, adaptive, multiarm proof of concept study for early
and accurate decisions on a candidate compound’s (or
combination of compounds) ongoing development for the
prevention of Alzheimer’s dementia [66]. We reason that
such distributed infrastructures that support clinical research
for societal gain will be essential for the future of AD
research.SSU 5.4.0 DTD  JALZ2137_proof 5. Conclusions
Studies and trials in preclinical AD have a solid scientific
basis and hold significant promise as part of the future AD
research landscape. In this scenario, a number of ethical
challenges, mainly related to determining appropriate risk-
benefit ratios and disclosing individuals’ biomarker status,
arise. Determining the acceptable risk-benefit ratio will
require improving public understanding of the relevant
issues, such as the probabilistic over deterministic nature
of biomarkers. Finally, we consider that both blinded obser-
vational trials and transparent interventional trials should be
considered as standard for future studies in this field.
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1. Recent validation of pathophysiological AD bio-
markers and longitudinal studies on Alzheimer’s pa-
thology justify the performance of future preclinical
studies. We identify ethical concerns from asymp-
tomatic AD studies related to risk-benefit ratio and
genetic and biomarker disclosure as substantial
ethical obstacles for preclinical studies.
2. Asymptomatic individuals participating in clinical
trials should be educated on the risks and benefits
of participation to determine the ethically appro-
priate risk-benefit ratio.
3. Public engagement, focus groups and social support
using a unified vocabulary will be essential to
improve standards of care for current AD sufferers
and promote predictive testing. Such educational
measures will be fundamental to overcome societal
and legal obstacles and protect individuals from
discrimination.4 March 2016  8:42 pm  ce
Q7
J.L. Molinuevo et al. / Alzheimer’s & Dementia- (2016) 1-98
842
843
844
845
846
847
848
849
850
851
852
853
854
855
856
857
858
859
860
861
862
863
864
865
866
867
868
869
870
871
872
873
874
875
876
877
878
879
880
881
882
883
884
885
886
887
888
889
890
891
892
893
894
895
896
897
898
899
900
901
902
903
904
905
906
907
908
909
910
911
912
913
914
915
916
917
918
919
920
921
922
923
924
925
926
927
928
929
930
931
932
933
934
935
936
937
938
939
940
941
942
943
944
945
946
947
948
949
950
951
952
953
954
955
956
957
958
959
960
961
962
963References
[1] Alzheimer’s Disease International. Policy Brief for Heads of
Government: The Global Impact of Dementia 2013–2050; 2013.
[2] Giacobini E, Gold G. Alzheimer disease therapy—moving from
amyloid-b to tau. Nat Rev Neurol 2013;9:677–86.
[3] McKhann G, Drachman D, Folstein M, Katzman R, Price D,
Stadlan EM. Clinical diagnosis of Alzheimer’s disease: report of the
NINCDS-ADRDAWork Group under the auspices of Department of
Health and Human Services Task Force on Alzheimer’s Disease.
Neurology 1984;34:939–44.
[4] Dubois B, Feldman HH, Jacova C, DeKosky ST, Barberger-Gateau P,
Cummings J, et al. Research criteria for the diagnosis of Alzheimer’s
disease: revising the NINCDS–ADRDA criteria. Lancet Neurol 2007;
6:734–46.
[5] Dubois B, Feldman HH, Jacova C, Cummings JL, Dekosky ST,
Barberger-Gateau P, et al. Revising the definition of Alzheimer’s
disease: a new lexicon. Lancet Neurol 2010;9:1118–27.
[6] McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR,
Kawas CH, et al. The diagnosis of dementia due to Alzheimer’s
disease: Recommendations from the National Institute on Aging-
Alzheimer’s Association workgroups on diagnostic guidelines for
Alzheimer’s disease. Alzheimers Dement 2011;7:263–9.
[7] Albert MS, DeKosky ST, Dickson D, Dubois B, Feldman HH,
Fox NC, et al. The diagnosis of mild cognitive impairment due to
Alzheimer’s disease: Recommendations from the National Institute
on Aging-Alzheimer’s Association workgroups on diagnostic
guidelines for Alzheimer’s disease. Alzheimers Dement 2011;
7:270–9.
[8] Sperling RA, Aisen PS, Beckett LA, Bennett DA, Craft S, Fagan AM,
et al. Toward defining the preclinical stages of Alzheimer’s disease:
Recommendations from the National Institute on Aging-Alzheimer’s
Association workgroups on diagnostic guidelines for Alzheimer’s
disease. Alzheimers Dement 2011;7:280–92.
[9] Bateman RJ, Xiong C, Benzinger TL, Fagan AM, Goate A, Fox NC,
et al. Clinical and biomarker changes in dominantly inherited
Alzheimer’s disease. N Engl J Med 2012;367:795–804.
[10] Knopman DS, Jack CR Jr, Wiste HJ, Weigand SD, Vemuri P, Lowe V,
et al. Short-term clinical outcomes for stages of NIA-AA preclinical
Alzheimer disease. Neurology 2012;78:1576–82.
[11] Mormino EC, Betensky RA, Hedden T, Schultz AP, Ward A,
Huijbers W, et al., Alzheimer’s Disease Neuroimaging Initiative.
Amyloid and APOE epsilon4 interact to influence short-term decline
in preclinical Alzheimer disease. Neurology 2014;82:1760–7.
[12] Reiman EM, Quiroz YT, Fleisher AS, Chen K, Velez-Pardo C,
Jimenez-Del-Rio M, et al. Brain imaging and fluid biomarker
analysis in young adults at genetic risk for autosomal dominant
Alzheimer’s disease in the presenilin 1 E280A kindred: a case-
control study. Lancet Neurol 2012;11:1048–56.
[13] Villemagne VL, Burnham S, Bourgeat P, Brown B, Ellis KA,
Salvado O, et al. Amyloid beta deposition, neurodegeneration, and
cognitive decline in sporadic Alzheimer’s disease: a prospective
cohort study. Lancet Neurol 2013;12:357–67.
[14] Vos SJ, Xiong C, Visser PJ, JasielecMS, Hassenstab J, Grant EA, et al.
Preclinical Alzheimer’s disease and its outcome: a longitudinal cohort
study. Lancet Neurol 2013;12:957–65.
[15] Cummings JL, Morstorf T, Zhong K. Alzheimer’s disease
drug-development pipeline: few candidates, frequent failures. Alz-
heimers Res Ther 2014;6:37.
[16] Emanuel EJ, Wendler D, Grady C. What makes clinical research
ethical? JAMA 2000;283:2701–11.
[17] Bateman RJ, Aisen PS, De Strooper B, Fox NC, Lemere CA,
Ringman JM, et al. Autosomal-dominant Alzheimer’s disease: a
review and proposal for the prevention of Alzheimer’s disease.
Alzheimers Res Ther 2011;3:1.
[18] Hauser PS, Ryan RO. Impact of Apolipoprotein E on Alzheimer’s
Disease. Curr Alzheimer Res 2013;10:809–17.SSU 5.4.0 DTD  JALZ2137_proof [19] Farrer LA, Cupples LA, Haines JL, Hyman B, Kukull WA, Mayeux R,
et al. Effects of age, sex, and ethnicity on the association between
apolipoprotein E genotype and Alzheimer disease. A meta-analysis.
JAMA 1997;278:1349–56.
[20] Jack CR, Knopman DS, Jagust WJ, Petersen RC, Weiner MW,
Aisen PS, et al. Tracking pathophysiological processes in Alzheimer’s
disease: an updated hypothetical model of dynamic biomarkers.
Lancet Neurol 2013;12:207–16.
[21] Taylor F, Huffman MD, Macedo AF, Moore TH, Burke M,
Davey Smith G, et al. Statins for the primary prevention of
cardiovascular disease. Cochrane Database Syst Rev 2013;
1:CD004816.
[22] Haba T, Mabuchi H, Yoshimura A, Watanabe A, Wakasugi T,
Tatami R, et al. Effects of ML-236b (compactin) on sterol synthesis
and low density lipoprotein receptor activities in fibroblasts of patients
with homozygous familial hypercholesterolemia. J Clin Invest 1981;
67:1532–40.
[23] Moulder KL, Snider BJ, Mills SL, Buckles VD, Santacruz AM,
Bateman RJ, et al. Dominantly Inherited Alzheimer Network:
facilitating research and clinical trials. Alzheimers Res Ther 2013;
5:48.
[24] Reiman EM, Langbaum JB, Fleisher AS, Caselli RJ, Chen K,
Ayutyanont N, et al. Alzheimer’s Prevention Initiative: a plan to
accelerate the evaluation of presymptomatic treatments. J Alzheimers
Dis 2011;26(Suppl 3):321–9.
[25] Sperling RA, Rentz DM, Johnson KA, Karlawish J, Donohue M,
Salmon DP, et al. The A4 Study: Stopping AD before Symptoms
Begin? Sci Transl Med 2014;6:228fs13.
[26] Roses AD, Saunders AM, Lutz MW, Zhang N, Hariri AR, Asin KE,
et al. New applications of disease genetics and pharmacogenetics to
drug development. Curr Opin Pharmacol 2014;14:81–9.
[27] Vellas B, Carrillo MC, Sampaio C, Brashear HR, Siemers E,
Hampel H, et al. Designing drug trials for Alzheimer’s disease:
What we have learned from the release of the phase III antibody trials:
A report from the EU/US/CTAD Task Force. Alzheimers Dement
2013;9:438–44.
[28] OECD (2014), “Unleashing the Power of Big Data for Alzheimer’s
Disease and Dementia Research: Main Points of the OECD Expert
Consultation on Unlocking Global Collaboration to accelerate Innova-
tion for Alzheimer’s Disease and Dementia”, OECD Digital Economy
Papers, No. 233, OECD Publishing. http://dx.doi.org/10.1787/
5jz73kvmvbwb-en.
[29] Aizenstein HJ, Nebes RD, Saxton JA, Price JC, Mathis CA,
Tsopelas ND, et al. Frequent amyloid deposition without significant
cognitive impairment among the elderly. Arch Neurol 2008;
65:1509–17.
[30] Price JL, McKeel DW, Buckles VD, Roe CM, Xiong C, GrundmanM,
et al. Neuropathology of nondemented aging: Presumptive
evidence for preclinical Alzheimer disease. Neurobiol Aging 2009;
30:1026–36.
[31] Landau SM, Mintun MA, Joshi AD, Koeppe RA, Petersen RC,
Aisen PS, et al. Amyloid deposition, hypometabolism, and longitudi-
nal cognitive decline. Ann Neurol 2012;72:578–86.
[32] Donohue MC, Sperling RA, Salmon DP, et al. The preclinical
Alzheimer cognitive composite: Measuring amyloid-related decline.
JAMA Neurol 2014;71:961–70.
[33] Roe CM, Fagan AM, Grant EA, Hassenstab J, Moulder KL, Maue
Dreyfus D, et al. Amyloid imaging and CSF biomarkers in predicting
cognitive impairment up to 7.5 years later. Neurology 2013;
80:1784–91.
[34] Rowe CC, Bourgeat P, Ellis KA, Brown B, Lim YY, Mulligan R, et al.
Predicting Alzheimer disease with b-amyloid imaging: Results from
the Australian imaging, biomarkers, and lifestyle study of ageing.
Ann Neurol 2013;74:905–13.
[35] Kim SY, Karlawish J, Berkman BE. Ethics of genetic and biomarker
test disclosures in neurodegenerative disease prevention trials.
Neurology 2015;84:1488–94.14 March 2016  8:42 pm  ce
Q8
Q9
10
11
J.L. Molinuevo et al. / Alzheimer’s & Dementia- (2016) 1-9 9
964
965
966
967
968
969
970
971
972
973
974
975
976
977
978
979
980
981
982
983
984
985
986
987
988
989
990
991
992
993
994
995
996
997
998
999
1000
1001
1002
1003
1004
1005
1006
1007
1008
1009
1010
1011
1012
1013
1014
1015
1016
1017
1018
1019
1020
1021
1022
1023
1024
1025
1026
1027
1028
1029
1030
1031
1032
1033
1034
1035
1036
1037
1038
1039
1040
1041
1042
1043
1044
1045
1046
1047
1048
1049
1050
1051
1052
1053
1054
1055
1056
1057
1058
1059
1060
1061
1062
1063
1064
1065
1066
1067
1068
1069[36] Lingler JH, Klunki WE. Disclosure of amyloid imaging results to
research participants: Has the time come? Alzheimers Dement 2013;
9:741–7442.
[37] Roberts JS, Dunn LB, Rabinovici GD. Amyloid imaging, risk
disclosure and Alzheimer’s disease: ethical and practical issues.
Neurodegener Dis Manag 2013;3:219–29.
[38] Epstein S. Impure Science: AIDS, Activism and the Politics of
Knowledge. UC Press; 1998.
[39] Rudick R, Polman C, Clifford D, Miller D, Steinman L. Natalizumab:
bench to bedside and beyond. JAMA Neurol 2013;70:172–82.
[40] King N. Defining and Describing Benefit Appropriately in Clinical
Trials. J Law Med Ethics 2000;28:332–43.
[41] Albert SM, Sano M, Marder K, Jacobs DM, Brandt J, Albert M, et al.
Participation in clinical trials and long-term outcomes in Alzheimer’s
disease. Neurology 1997;49:38–43.
[42] Avent C, Curry L, Gregory S, Marquardt S, Pae L, Wilson D, et al.
Establishing the motivations of patients with dementia and cognitive
impairment and their carers in joining a dementia research register
(DemReg). Int Psychogeriatr 2013;25:963–71.
[43] Haga SB, BarryWT,Mills R, Ginsburg GS, Svetkey L, Sullivan J, et al.
Public Knowledge of and Attitudes Toward Genetics and Genetic
Testing. Genet Test Mol Biomarkers 2013;17:327–35.
[44] Cupples LA, Farrer LA, Sadovnick AD, Relkin N, Whitehouse P,
Green RC. Estimating risk curves for first-degree relatives of patients
withAlzheimer’s disease: theREVEALstudy.GenetMed2004;6:192–6.
[45] Lautenbach DM, Christensen KD, Sparks JA, Green RC.
Communicating genetic risk information for common disorders in
the era of genomic medicine. Annu Rev Genomics Hum Genet
2013;14:491–513.
[46] Green RC, Roberts JS, Cupples LA, Relkin NR, Whitehouse PJ,
Brown T, et al. Disclosure of APOE Genotype for Risk of Alzheimer’s
Disease. N Engl J Med 2009;361:245–54.
[47] Bird TD. Outrageous fortune: the risk of suicide in genetic testing for
Huntington disease. Am J Hum Genet 1999;64:1289–92.
[48] Lineweaver TT, Bondi MW, Galasko D, Salmon DP. Effect of
Knowledge of APOE Genotype on Subjective and Objective Memory
Performance inHealthyOlderAdults.AmJPsychiatry 2014;171:201–8.
[49] Alzheimer Europe - Research - Value of Knowing n.d. Available from:
http://www.alzheimer-europe.org/Research/Value-of-Knowing. Ac-
cessed February, 2015.
[50] Chao S, Roberts JS, Marteau TM, Silliman R, Cupples LA, Green RC.
Health behavior changes after genetic risk assessment forAlzheimer dis-
ease: The REVEAL Study. Alzheimer Dis Assoc Disord 2008;22:94–7.
[51] Vernarelli JA, Roberts JS, Hiraki S, Chen CA, Cupples LA, Green RC.
Effect of Alzheimer disease genetic risk disclosure on dietary
supplement use. Am J Clin Nutr 2010;91:1402–7.
[52] Billings AG, Moos RH. Life stressors and social resources affect
posttreatment outcomes among depressed patients. J Abnorm Psychol
1985;94:140–53.SSU 5.4.0 DTD  JALZ2137_proof [53] Kolata G. HowDoYou Live KnowingYouMight Have an Alzheimer’s
Gene? The New York Times 2012 June 7, 2012.
[54] Ryman DC, Acosta-Baena N, Aisen PS, Bird T, Danek A, Fox NC,
et al. Symptom onset in autosomal dominant Alzheimer disease: A
systematic review and meta-analysis. Neurology 2014;83:253–60.
[55] Steinbart EJ, Poorkaj P, Smith CO, Bird TD. Impact of DNA testing for
early-onset familial Alzheimer disease and frontotemporal dementia.
Arch Neurol 2001;58:1828–31.
[56] Harkins K, Sankar P, Sperling R, Grill JD, Green RC, Johnson KA,
et al. Development of a process to disclose amyloid imaging results
to cognitively normal older adult research participants. Alzheimers
Res Ther 2015;7:26.
[57] Sperling R, Karlawish J, Grill J, Burns J, Sultzer D, Johnson K, et al.,
for the Alzheimer’s Disease Cooperative Study. Disclosing Amyloid
Status in the Anti-Amyloid Treatment of Asymptomatic Alzheimer’s
Disease (A4) Study. Washington, USA: AAIC; 2015.
[58] L€opp€onen M, R€aih€a I, Isoaho R, Vahlberg T, Kivel€a S-L. Diagnosing
cognitive impairment and dementia in primary health care – a more
active approach is needed. Age Ageing 2003;32:606–12.
[59] Boustani M, Peterson B, Hanson L, Harris R, Lohr KN, U.S.
Preventive Services Task Force. Screening for dementia in primary
care: a summary of the evidence for the U.S. Preventive Services
Task Force. Ann Intern Med 2003;138:927–37.
[60] Valcour VG, Masaki KH, Curb JD, Blanchette PL. The detection of
dementia in the primary care setting. Arch Intern Med 2000;
160:2964–8.
[61] Alzheimer Europe - Alzheimer Europe - Our work - Completed
projects - 2006: Dementia Carers’ Survey n.d. Available from: http://
www.alzheimer-europe.org/Alzheimer-Europe/Our-work/Completed-
projects/2006-Dementia-Carers-Survey. Accessed November 27,
2014.
[62] Bond J, Stave C, Sganga A, O’Connell B, Stanley RL. Inequalities in
dementia care across Europe: key findings of the Facing Dementia
Survey. Int J Clin Pract Suppl 2005;:8–14. Q
[63] Blendon RJ, Benson JM, Wikler EM, Weldon KJ, Georges J,
Baumgart M, et al. The Impact of Experience with a Family Member
with Alzheimer’s Disease on Views about the Disease across Five
Countries. Int J Alzheimers Dis 2012;2012:903645.
[64] Arias JJ, Karlawish J. Confidentiality in preclinical Alzheimer disease
studies When research and medical records meet. Neurology 2014;
82:725–9.
[65] Coppieters Y, Leve^que A. Ethics, privacy and the legal framework
governing medical data: opportunities or threats for biomedical and
public health research? Arch Public Health 2013;71:15.
[66] Ritchie CW, Molinuevom JL, Truyen L, Satlin A, Van der Geyten S,
Lovestone S, on behalf of the EPAD Consortium. Development of
interventions for the secondary prevention of Alzheimer’s dementia:
the European Prevention of Alzheimer’s Dementia (EPAD) project.
Lancet Psychiatry 2016;3:179–86. Q14 March 2016  8:42 pm  ce
1070
1071
1072
1073
1074
1075
1076
1077
1078
1079
1080
1081
1082
1083
1084
1085
